Skip to main content Skip to section navigation Skip to footer
OPKO Health, Inc. Corporate homepage OPKO Health, Inc. Corporate homepage
  • Company
    • About Us
    • Team
    • Partner With Us
    • Careers
    • Contact
  • Pipeline
  • Science & Technology
    • ModeX Platforms
    • Long-Acting Biologics & Peptides
    • Publications
  • Global Pharmaceuticals
    • Our Medicines
    • Global Operations
  • Investors
    • Investors Overview
    • News / Events
    • Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Governance
Site Announcement

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Read the news release
Visit BioReference Health

Press Releases

Investors

  • Investors Overview
  • News / Events
    • News / Events Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Information
    • Company Profile
    • Proxy Materials
    • Contacts
    • FAQ
  • Financial Information
    • Financial Information Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Chart
    • Historical Data
  • SEC Filings
    • SEC Filings Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Form 8937
  • Governance
    • Governance Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News / Events

  • News / Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Oct 1, 2007 2:12 pm EDT
OPKO Health Appoints Pascal J. Goldschmidt to Board of Directors
Sep 18, 2007 8:00 am EDT
OPKO Health to Present at UBS 2007 Global Life Sciences Conference
Aug 30, 2007 10:55 am EDT
Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Jul 12, 2007 8:00 am EDT
Opko Health, Inc. Announces Early Termination of Hart-Scott-Rodino Waiting Period for Proposed Purchase of Shares by Dr. Phillip Frost
Jul 11, 2007 8:00 am EDT
Opko Health Initiates Phase 3 Trial of Bevasiranib for the Treatment of AMD
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 46
  • Page 47
  • Page 48
  • Page 49
  • Page 50
  • Page 51
  • Page 52
  • Page 53
  • Page 54
  • Page 55
rss_feed News RSS

Sign up to receive company updates straight to your inbox.

Sign Up for Email Alerts

4400 Biscayne Boulevard
Miami, FL 33137

305-575-4100 / contact@opko.com

©2026 OPKO Health, Inc. All Rights Reserved.
  • Privacy Policy
  • Terms Of Use
  • Sitemap
  • Accessibility Statement
  • Consent Preferences